TNF-δ in the pathophysiology of psoriasis;Le TNF-δ dans la physiopathologie du psoriasis

Annales de Dermatologie et de Venereologie

Volumn 133, Issue 2, 2006, Pages 174-180

  Rozieres, A ^a   Hennino, A ^a   Nicolas, J F ^a,b  

^a University Lyon i   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYCLOSPORIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR DELTA; TUMOR NECROSIS FACTOR DERIVATIVE; UNCLASSIFIED DRUG; CYTOKINE; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; CELL PROLIFERATION; CYTOKINE PRODUCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KERATINOCYTE; PATHOGENESIS; PATHOPHYSIOLOGY; PSORIASIS; TREATMENT OUTCOME; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; FORECASTING; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; RESEARCH; REVIEW; SKIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHEMOKINES; CYTOKINES; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; IMMUNOGLOBULIN G; KERATINOCYTES; LYMPHOCYTE ACTIVATION; MICE; PHENOTYPE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RESEARCH; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645986964     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(06)70873-0     Document Type: Article

References (40)

1. Berard F, Guillot I, Saad N, Nicolas JF. Comment comprendre le psoriasis ? Rev Prat 2004;54:28-34.
2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113: 1664-75.
3. Thivolet,J . Nicolas, JF. EJD Book Series John Libbey Eurotext (1998).
4. Berard F, Nicolas JF. Physiopathologie du psoriasis. Ann Dermatol Venereol 2003;130:837-42.
5. Barker CL, McHale MT, Gillies AK, Waller J, Pearce DM, Osborne J et al. The development and characterization of an in vitro model of psoriasis. J Invest Dermatol 2004;123:892-901.
6. 4 monoclonal antibody therapy in severe psoriasis. J Autoimmun 1992;5:465-77.
7. Nicolas JF, Morel P, Revillard JP, Thivolet J. Immunointervention dans le psoriasis. Conséquences pathogénétiques. Ann Dermatol Venereol 1993;120:246-7.
8. Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 2003;13:471-3.
9. Bayliffe AI, Brigandi RA, Wilkins HJ, Levick MP. Emerging therapeutic targets in psoriasis. Curr Opin Pharmacol 2004;4:306-10.
10. Ritchlin CT. Comparison of methotrexate and cyclosporine therapy in psoriasis. Curr Rheumatol Rep 2004;6: 289.
11. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP. CD4 antibody treatment of severe psoriasis. Lancet 1991;338:321.
12. Prinz J, Braun-Falco O, Meurer M, Daddona P, Reiter C, Rieber P, Riethmuller G. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991;338:320-1.
13. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999;155:145-58.
14. Schon MP. Animal models of psoriasis - what can we learn from them? J Invest Dermatol 1999;112:405-10.
15. Bour H, Puisieux I, Even J, Kourilsky P, Favrot M, Musette P, Nicolas JF. T-cell repertoire analysis in chronic plaque psoriasis suggests an antigen-specific immune response. Hum Immunol 1999,60:665-76.
16. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
17. Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, Dooley LT, Fasanmade AA, Wagner CL. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003;48:68-75.
18. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005;11:43-9.
19. Boehncke WH. The alpha-defensins HNP-1 and HN P-2 are dominant self-peptides presented by HLA class-II molecules in lesional psoriatic skin. Eur J Dermatol 2004;14:142-5.
20. Yamamoto T, Katayama I, Nishioka K. Clinical analysis of staphylococcal superantigen hyper-reactive patients with psoriasis vulgaris. Eur J Dermatol 1998;8:325-9.
21. Santamaria-Babi LF CLA(+) T cells in cutaneous diseases. Eur J Dermatol 2004;14:13-8.
22. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004;199:731-6.
23. Capuano M, Lesnoni la Parola I, Masini C, Uccini S, Cerimele D. Immunohistochemical study of the early histopathologic changes occurring in trauma-injured skin of psoriatic patients. Eur J Dermatol 1999;9:102-6.
24. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993;101: 701-5.
25. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003; 171:3262-9.
26. Groves RW, Allen MH, Ross EL, Barker JN, MacDonald DM. Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 1995;132:345-52.
27. Victor FC, Gottlieb AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol 2002;1:264-75.
28. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK, 3rd. Biology of tumor necrosis factor-alpha - implications for psoriasis. Exp Dermatol 2004;13:193-222.
29. Iversen L, Johansen C, Kragballe K. Signal transduction pathways in human epidermis. Eur J Dermatol 2005;15:4-12.
30. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH. Proteasome Inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 2002;109:671-9.
31. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999;135:1104-10.
32. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J Am Acad Dermatol 1991;24:675-85.
33. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
34. Kimber I, Cumberbatch M, Dearman RJ, Bhushan M, Griffiths CE. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br J Dermatol 2000;142:401-12.
35. Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004;279:32633-42.
36. Pastore S, Mascia F, Mariotti F, Dattilo C, Girolomoni G. Chemokine networks in inflammatory skin diseases. Eur J Dermatol 2004;14:203-8.
37. Giustizieri ML, Mascia F, Frezzolini A, De Pita O, Chinni LM, Giannetti A et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001;107:871-7.
38. Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, Plewig G. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 1994;24:593-8.
39. Koch F, Heufler C, Kampgen E, Schneeweiss D, Bock G, Schuler G. Tumor necrosis factor alpha maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation. J Exp Med 1990;171:159-71.
40. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004;25:563-8.